ESR1 and neoplasm: Thus, we leveraged the ability to inhibit ER signaling and modulate tumor immunity, and conducted a randomized phase II clinical trial combining vorinostat with the selective ER modulator tamoxifen and the immune checkpoint inhibitor pembrolizumab (NCT02395627), given either on day 1 of cycle 1 or on day 1 of cycle 2.